Bio-Path Holdings Inc (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings Inc (NASDAQ:BPTH) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 207,200 shares, a decrease of 21.7% from the May 30th total of 264,600 shares. Approximately 12.1% of the shares of the company are sold short. Based on an average daily trading volume, of 331,500 shares, the short-interest ratio is presently 0.6 days.

A hedge fund recently bought a new stake in Bio-Path stock. Gainplan LLC purchased a new position in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $204,000. Bio-Path makes up approximately 0.2% of Gainplan LLC’s investment portfolio, making the stock its 21st largest position. Gainplan LLC owned approximately 0.40% of Bio-Path as of its most recent SEC filing. Institutional investors own 10.77% of the company’s stock.

Shares of NASDAQ:BPTH traded down $0.15 on Thursday, reaching $12.95. The company’s stock had a trading volume of 38,400 shares, compared to its average volume of 2,033,690. The business has a 50-day moving average price of $13.68. Bio-Path has a 52-week low of $1.61 and a 52-week high of $73.52.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, May 16th. The company reported ($0.89) EPS for the quarter.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Read More: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.